ArticleCancer cell2019
Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 565 papers.
0numbers the graph read from it
0cells of the map it votes in
565citing papers in PubMed
32.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
565 citing papers in PubMed, 838 citations in OpenAlex.
- The role of RNA modifications in cancer translational control.RNA biology · 2026Review
- The role, regulatory mechanisms, and therapeutic implications of FTO in gastrointestinal cancer.Genes & diseases · 2026Review
- Hepatic Lipid Stress Drives Metabolic Dysfunction-Associated Steatohepatitis Progression through FTO O-GlcNAcylation-Induced m6A Demethylation of HRAS.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- m6A methylation in ferroptosis regulation: mechanisms, targets, and therapeutic interventions.Journal of advanced research · 2026Review
- The cellular landscape of druggable RNA-binding proteins.Nature reviews. Drug discovery · 2026Review
- FTO/m6A Regulate Prenatal Nicotine-Induced eNOS Uncoupling and BP Susceptibility.Hypertension (Dallas, Tex. : 1979) · 2026Article
- How Epitranscriptomic Machinery Senses Environmental Cues.Advanced biology · 2026Review
- Targeting the SETD2-FTO-KIT pathway as a pharmacological strategy for TKI-refractory GIST.Acta pharmaceutica Sinica. B · 2026Article
- Synthesis and Binding Affinity Insights of 2-Phenyl-1H-Benzimidazole Inhibitors Targeting FTO by Spectroscopic Characterization and Molecular Docking.Journal of molecular recognition : JMR · 2026Article
- Targeting MYC-Driven Cancers: From Oncogenic Addiction to Therapeutic Vulnerability.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- FTO-Driven m6A Demethylation of TNC Promotes Epithelial-Mesenchymal Transition and Gastric Cancer Metastasis.Biomedicines · 2026Article
- AL398, A Novel NSUN6 Inhibitor, Attenuates Epithelial-Mesenchymal Transition and Metastasis in Endometrial Cancer by Abrogating m5C-Dependent Stabilization of Snail mRNA.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Epigenetic Factor Dysregulation and Distinct Expression Signatures in Retinoblastoma: A Transcriptomic Analysis.Investigative ophthalmology & visual science · 2026Article
- USP30 senses serine/glycine levels to regulate serine biosynthesis and colorectal tumorigenesis by deubiquitinating FTO.Cell death and differentiation · 2026Article
- Review
- Interplay between N6-methyladenosine RNA methylation and protein lactylation: a novel crosstalk linking metabolism and epigenetic regulation in human diseases.Journal of translational medicine · 2026Review
- The lncRNA-m6A axis in cancer: a bidirectional regulatory network in tumor progression and therapeutic resistance.Journal of translational medicine · 2026Review
- A targetable FTO/SLC7A11/CBS/CTH axis controls cysteine metabolism, growth and survival in NSCLC.Science advances · 2026Article
- Review
- Chromosomal rearrangement-enhanced mRNA stability drives the oncogenic potential of fusion genes in pediatric leukemia.Haematologica · 2026Article
505 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
28 authors at 10 institutions in 2 countries.
Yue HuangState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of the Chinese Academy of Sciences, Beijing 100049, China.
Rui SuDepartment of Systems Biology and Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA 91010, USA; Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH 45219, USA.
Yue ShengDepartment of Medicine, UF Health Cancer Center, University of Florida, Gainesville, FL 32610, USA; Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
Lei DongDepartment of Systems Biology and Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA 91010, USA; Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH 45219, USA.
Ze DongState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Hongjiao XuState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of the Chinese Academy of Sciences, Beijing 100049, China.
Tengfeng NiState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Zijie Scott ZhangDepartment of Chemistry and Institute for Biophysical Dynamics, The University of Chicago, Chicago, IL 60637, USA.
Tao ZhangState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Chenying LiDepartment of Systems Biology and Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA 91010, USA; Key Laboratory of Hematopoietic Malignancies, Department of Hematology, The First Affiliated Hospital Zhejiang University, Hangzhou, Zhejiang 310003, China.
Li HanDepartment of Systems Biology and Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA 91010, USA.
Zhenyun ZhuCAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Fulin LianCAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Jiangbo WeiDepartment of Chemistry and Institute for Biophysical Dynamics, The University of Chicago, Chicago, IL 60637, USA.
Qiangqiang DengShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Yungui WangKey Laboratory of Hematopoietic Malignancies, Department of Hematology, The First Affiliated Hospital Zhejiang University, Hangzhou, Zhejiang 310003, China.
Mark WunderlichDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Zhiwei GaoState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Guoyu PanUniversity of the Chinese Academy of Sciences, Beijing 100049, China; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Dafang ZhongState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of the Chinese Academy of Sciences, Beijing 100049, China.
Hu ZhouUniversity of the Chinese Academy of Sciences, Beijing 100049, China; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Naixia ZhangUniversity of the Chinese Academy of Sciences, Beijing 100049, China; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Jianhua GanSchool of Life Sciences, Fudan University, Shanghai 200433, China.
Hualiang JiangState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of the Chinese Academy of Sciences, Beijing 100049, China.
James C MulloyDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Zhijian QianDepartment of Medicine, UF Health Cancer Center, University of Florida, Gainesville, FL 32610, USA; Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA. Electronic address: zhijian.qian@medicine.ufl.edu.
Jianjun ChenDepartment of Systems Biology and Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA 91010, USA; Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH 45219, USA. Electronic address: jianchen@coh.org.
Cai-Guang YangState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of the Chinese Academy of Sciences, Beijing 100049, China. Electronic address: yangcg@simm.ac.cn.
Shanghai Institute of Materia Medica · CNChinese Academy of Sciences · CNUniversity of Chinese Academy of Sciences · CNUniversity of Cincinnati Medical Center · USCincinnati Children's Hospital Medical Center · USFirst Affiliated Hospital Zhejiang University · CNUniversity of Chicago · USUniversity of Florida Health · USCity of Hope · USFudan University · CN
Funding
Targeting FTO to treat acute myeloid leukemiaR01CA243386 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2020 to 2024
$2.8MThe role and mechanism of METTL3/METTL14-mediated RNA modification in the pathogenesis and drug-resistance of AMLR01CA236399 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2019 to 2023
$2.3MTargeting TET1 signaling to treat acute myeloid leukemiaR01CA211614 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2017 to 2021
$2.3MThe function and underlying mechanism of TET1 in myelodysplastic syndromesR01DK124116 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2020 to 2023
$2.2MThe role and mechanism of FTO in leukemogenesis and drug responseR01CA214965 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2017 to 2021
$2.1MTherapeutic insights through patient derived leukemia xenograftsR50CA211404 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI Mark Wunderlich · 2016 to 2026
$1.9MThe role and functional mechanism of TET1 in MLL-rearranged leukemiaR01CA178454 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2014 to 2018
$1.7MThe role of EVI1-induced hypermethylation in leukemogenesis.R01HL131444 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI QIAN, ZHIJIAN · 2016 to 2019
$1.6MThe molecular mechanism of clonal dominance in 5q(del) MDSR01DK107615 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI QIAN, ZHIJIAN · 2016 to 2019
$1.4MThe role, mechanism and therapeutic potential of TET1 in MDSR56DK120282 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2018 to 2018
$100kNCI NIH HHS R01 CA178454NCI NIH HHS R01 CA211614NCI NIH HHS R01 CA214965NCI NIH HHS R01 CA236399NCI NIH HHS R01 CA243386NCI NIH HHS R50 CA211404NHLBI NIH HHS R01 HL131444NIDDK NIH HHS R01 DK107615NIDDK NIH HHS R01 DK124116NIDDK NIH HHS R56 DK120282
Abstract
FTO, an mRNA N
Indexed as
Alpha-Ketoglutarate-Dependent Dioxygenase FTOAnimalsAntineoplastic AgentsApoptosisCell Cycle CheckpointsCell DifferentiationCell ProliferationDose-Response Relationship, DrugEnzyme InhibitorsHumansLeukemia, Myeloid, AcuteMethylationMice, Inbred BALB CMice, Inbred NODMice, TransgenicMolecular Targeted TherapyAlpha-Ketoglutarate-Dependent Dioxygenase FTOAntineoplastic AgentsEnzyme InhibitorsFTO protein, humanRNA, Messengeracute myeloid leukemiacancer therapyFTO inhibitorRNA epitranscriptomicsstructure-based designtarget validation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.